https://www.adaptimmune.com/ https://www.adaptimmune.com/our-company/board-of-directors https://www.adaptimmune.com/pipeline https://www.adaptimmune.com/pipeline/clinical-pipeline https://www.adaptimmune.com/technology https://www.adaptimmune.com/technology/overview https://www.adaptimmune.com/technology/publications https://www.adaptimmune.com/investors-and-media https://www.adaptimmune.com/investors-and-media/overview https://www.adaptimmune.com/investors-and-media/news-center https://www.adaptimmune.com/investors-and-media/news-center/media https://www.adaptimmune.com/investors-and-media/news-center/press-releases https://www.adaptimmune.com/investors-and-media/news-center/publications https://www.adaptimmune.com/investors-and-media/news-center/events https://www.adaptimmune.com/investors-and-media/news-center/email-alerts https://www.adaptimmune.com/investors-and-media/financial-information-governance https://www.adaptimmune.com/investors-and-media/financial-information-governance/general-meeting-merger https://www.adaptimmune.com/investors-and-media/financial-information-governance/company-information https://www.adaptimmune.com/investors-and-media/financial-information-governance/financial-results https://www.adaptimmune.com/investors-and-media/financial-information-governance/board-of-directors https://www.adaptimmune.com/investors-and-media/financial-information-governance/governance-documents https://www.adaptimmune.com/investors-and-media/financial-information-governance/annual-shareholder-meeting https://www.adaptimmune.com/investors-and-media/financial-information-governance/faq https://www.adaptimmune.com/investors-and-media/financial-information-governance/contacts https://www.adaptimmune.com/investors-and-media/financial-information-governance/adaptimmune-ltd-report https://www.adaptimmune.com/investors-and-media/stock-data/quote https://www.adaptimmune.com/investors-and-media/stock-data/charts https://www.adaptimmune.com/investors-and-media/stock-data/historical-data https://www.adaptimmune.com/investors-and-media/stock-data/analyst-coverage https://www.adaptimmune.com/investors-and-media/sec-filings https://www.adaptimmune.com/investors-and-media/sec-filings/overview https://www.adaptimmune.com/investors-and-media/sec-filings/all-sec-filings https://www.adaptimmune.com/investors-and-media/sec-filings/annual-reports https://www.adaptimmune.com/investors-and-media/sec-filings/quarterly-reports https://www.adaptimmune.com/investors-and-media/sec-filings/section-16-filings https://www.adaptimmune.com/contact https://www.adaptimmune.com/investors-and-media/news-center/press-releases/detail/290/adaptimmune-announces-changes-to-board-and-executive https://www.adaptimmune.com/investors-and-media/news-center/press-releases/detail/289/adaptimmune-announces-delisting-from-nasdaq https://www.adaptimmune.com/investors-and-media/news-center/press-releases/detail/288/adaptimmune-reports-q2-financial-results-and-provides https://www.adaptimmune.com/investors-and-media/news-center/press-releases/detail/287/adaptimmune-announces-entry-into-definitive-agreement-for https://www.adaptimmune.com/investors-and-media/news-center/press-releases/detail/286/adaptimmune-reports-q1-financial-results-and-provides https://www.adaptimmune.com/investors-and-media/news-center/press-releases/detail/285/adaptimmune-to-report-q1-2025-financial-and-business https://www.adaptimmune.com/investors-and-media/news-center/press-releases/detail/284/adaptimmune-provides-q4-and-full-year-2024-business-update https://www.adaptimmune.com/investors-and-media/news-center/press-releases/detail/283/adaptimmune-to-report-full-year-and-q4-2024-financial-and https://www.adaptimmune.com/investors-and-media/news-center/press-releases/detail/282/adaptimmune-to-participate-in-the-guggenheim-securities https://www.adaptimmune.com/investors-and-media/news-center/press-releases/detail/281/adaptimmune-announces-u-s-fda-breakthrough-therapy https://www.adaptimmune.com/investors-and-media/news-center/press-releases/detail/280/adaptimmune-announces-changes-to-its-executive-leadership https://www.adaptimmune.com/investors-and-media/news-center/press-releases/detail/279/first-patient-treated-with-adaptimmunes-tecelrar https://www.adaptimmune.com/investors-and-media/news-center/press-releases/detail/278/adaptimmune-reports-q3-2024-financial-and-business-updates https://www.adaptimmune.com/investors-and-media/news-center/press-releases/detail/277/adaptimmunes-lete-cel-achieves-primary-endpoint-in-pivotal https://www.adaptimmune.com/investors-and-media/news-center/press-releases/detail/276/adaptimmune-to-participate-in-scientific-and-medical https://www.adaptimmune.com/investors-and-media/news-center/press-releases/detail/275/adaptimmune-to-report-q3-2024-financial-and-business https://www.adaptimmune.com/investors-and-media/news-center/press-releases/detail/274/adaptimmune-to-participate-in-two-bank-conferences-this https://www.adaptimmune.com/investors-and-media/news-center/press-releases/detail/273/adaptimmune-reports-q2-2024-financial-and-business-updates https://www.adaptimmune.com/investors-and-media/news-center/press-releases/detail/272/adaptimmune-to-report-q2-2024-financial-and-business https://www.adaptimmune.com/investors-and-media/news-center/press-releases/detail/271/adaptimmune-receives-u-s-fda-accelerated-approval-of https://www.adaptimmune.com/investors-and-media/news-center/press-releases/detail/270/adaptimmune-to-present-data-from-planned-interim-analysis https://www.adaptimmune.com/investors-and-media/news-center/press-releases/detail/269/adaptimmune-and-galapagos-sign-clinical-collaboration https://www.adaptimmune.com/investors-and-media/news-center/press-releases/detail/268/adaptimmune-reports-q1-2024-financial-and-business-updates https://www.adaptimmune.com/investors-and-media/news-center/press-releases/detail/267/adaptimmune-secures-up-to-125-million-debt-financing-with https://www.adaptimmune.com/investors-and-media/news-center/press-releases/detail/266/adaptimmune-to-report-q1-2024-financial-and-business https://www.adaptimmune.com/investors-and-media/news-center/press-releases/detail/265/strategic-collaboration-between-adaptimmune-and-genentech https://www.adaptimmune.com/investors-and-media/news-center/press-releases/detail/264/results-of-adaptimmunes-spearhead-1-trial-with-afami-cel https://www.adaptimmune.com/investors-and-media/news-center/press-releases/detail/263/adaptimmune-reports-q4full-year-2023-financial-results-and https://www.adaptimmune.com/investors-and-media/news-center/press-releases/detail/262/adaptimmune-hires-chief-commercial-officer-in-advance-of-q3 https://www.adaptimmune.com/investors-and-media/news-center/press-releases/detail/261/adaptimmune-to-report-q4-and-full-year-2023-financial-and https://www.adaptimmune.com/investors-and-media/news-center/press-releases/detail/260/adaptimmune-announces-u-s-fda-acceptance-of-biologics https://www.adaptimmune.com/investors-and-media/news-center/press-releases/detail/259/adaptimmune-projects-sarcoma-franchise-to-deliver-us-peak https://www.adaptimmune.com/investors-and-media/news-center/press-releases/detail/258/adaptimmune-completes-submission-of-rolling-biologics https://www.adaptimmune.com/investors-and-media/news-center/press-releases/detail/257/adaptimmune-receives-transfer-of-ind-for-lete-cel-program https://www.adaptimmune.com/investors-and-media/news-center/press-releases/detail/256/adaptimmune-reports-third-quarter-financial-results-and https://www.adaptimmune.com/investors-and-media/news-center/press-releases/detail/255/adaptimmune-selects-adp-600-as-clinical-candidate-for https://www.adaptimmune.com/investors-and-media/news-center/press-releases/detail/254/adaptimmune-reports-positive-data-with-lete-cel1-from-an https://www.adaptimmune.com/investors-and-media/news-center/press-releases/detail/253/adaptimmune-reports-better-outcomes-for-people-with https://www.adaptimmune.com/investors-and-media/news-center/press-releases/detail/252/adaptimmune-to-report-q3-2023-financial-and-business https://www.adaptimmune.com/investors-and-media/news-center/press-releases/detail/251/next-generation-tcr-t-cell-therapy-adp-a2m4cd8 https://www.adaptimmune.com/investors-and-media/news-center/press-releases/detail/250/dr-karen-chagin-joins-adaptimmune-as-senior-vice-president https://www.adaptimmune.com/investors-and-media/news-center/press-releases/detail/249/adaptimmune-reports-second-quarter-financial-results-and https://www.adaptimmune.com/investors-and-media/news-center/press-releases/detail/248/adaptimmune-to-report-q2-2023-financial-and-business https://www.adaptimmune.com/investors-and-media/news-center/press-releases/detail/247/adaptimmune-announces-completion-of-strategic-combination https://www.adaptimmune.com/investors-and-media/news-center/press-releases/detail/246/adaptimmune-announces-70-of-people-with-advanced-synovial https://www.adaptimmune.com/investors-and-media/news-center/press-releases/detail/245/adaptimmune-reports-first-quarter-financial-results-and https://www.adaptimmune.com/investors-and-media/news-center/press-releases/detail/244/adaptimmune-to-report-q1-2023-financial-and-business https://www.adaptimmune.com/investors-and-media/news-center/press-releases/detail/243/adaptimmune-and-gsk-have-agreed-terms-for-transfer-of-prame https://www.adaptimmune.com/investors-and-media/news-center/press-releases/detail/242/adaptimmune-reports-fourth-quarter-and-full-year-financial https://www.adaptimmune.com/investors-and-media/news-center/press-releases/detail/241/adaptimmune-and-tcr2-therapeutics-announce-strategic https://www.adaptimmune.com/investors-and-media/news-center/press-releases/detail/240/adaptimmune-to-report-q4-and-full-year-2022-financial-and https://www.adaptimmune.com/investors-and-media/news-center/press-releases/detail/239/adaptimmune-announces-changes-to-board-of-directors https://www.adaptimmune.com/investors-and-media/news-center/press-releases/detail/238/publication-of-data-from-adaptimmunes-completed-phase-1 https://www.adaptimmune.com/investors-and-media/news-center/press-releases/detail/237/adaptimmune-announces-initiation-of-biologics-license https://www.adaptimmune.com/investors-and-media/news-center/press-releases/detail/236/data-from-cohort-1-of-spearhead-1-trial-at-ctos-continue-to https://www.adaptimmune.com/investors-and-media/news-center/press-releases/detail/235/adaptimmune-reports-third-quarter-financial-results-and https://www.adaptimmune.com/investors-and-media/news-center/press-releases/detail/234/adaptimmune-reports-increased-response-rate-and-durability https://www.adaptimmune.com/investors-and-media/news-center/press-releases/detail/233/adaptimmune-to-report-q3-2022-financial-and-business https://www.adaptimmune.com/investors-and-media/news-center/press-releases/detail/232/adaptimmune-enhances-its-pipeline-of-wholly-owned-cell https://www.adaptimmune.com/investors-and-media/news-center/press-releases/detail/231/adaptimmune-reports-positive-data-in-its-surpass-trial https://www.adaptimmune.com/investors-and-media/news-center/press-releases/detail/230/adaptimmune-to-host-live-virtual-event-to-review-phase-1 https://www.adaptimmune.com/investors-and-media/news-center/press-releases/detail/229/adaptimmune-reports-second-quarter-financial-results-and https://www.adaptimmune.com/investors-and-media/news-center/press-releases/detail/228/adaptimmune-to-report-q2-2022-financial-results-and https://www.adaptimmune.com/investors-and-media/news-center/press-releases/detail/227/clinical-responses-reported-across-patient-subgroups-with https://www.adaptimmune.com/investors-and-media/news-center/press-releases/detail/226/preclinical-proof-of-concept-data-supporting-future https://www.adaptimmune.com/investors-and-media/news-center/press-releases/detail/225/adaptimmune-reports-first-quarter-financial-results-and https://www.adaptimmune.com/investors-and-media/news-center/press-releases/detail/224/adaptimmune-announces-appointment-of-joanna-brewer-as-chief https://www.adaptimmune.com/investors-and-media/news-center/press-releases/detail/223/adaptimmune-to-report-q1-2022-financial-results-and https://www.adaptimmune.com/investors-and-media/news-center/press-releases/detail/222/adaptimmune-presents-mage-a4-expression-data-from-its https://www.adaptimmune.com/investors-and-media/news-center/press-releases/detail/221/adaptimmune-reports-fourth-quarter-and-full-year-2021 https://www.adaptimmune.com/investors-and-media/news-center/press-releases/detail/205/adaptimmune-to-report-q4-and-full-year-2021-financial https://www.adaptimmune.com/investors-and-media/news-center/press-releases/detail/204/adaptimmune-announces-appointment-of-cintia-piccina-as https://www.adaptimmune.com/investors-and-media/news-center/press-releases/detail/203/translational-data-at-sitc-2021-from-adaptimmunes-phase https://www.adaptimmune.com/investors-and-media/news-center/press-releases/detail/202/adaptimmune-reports-positive-results-from-its-pivotal https://www.adaptimmune.com/investors-and-media/news-center/press-releases/detail/201/adaptimmune-reports-third-quarter-financial-results-and https://www.adaptimmune.com/investors-and-media/news-center/press-releases/detail/200/adaptimmune-to-report-q3-2021-financial-results-and https://www.adaptimmune.com/investors-and-media/news-center/press-releases/detail/199/adaptimmune-to-present-data-updates-at-upcoming-ctos-and https://www.adaptimmune.com/investors-and-media/news-center/press-releases/detail/198/adaptimmune-announces-clinical-responses-across-five-solid https://www.adaptimmune.com/investors-and-media/news-center/press-releases/detail/197/adaptimmune-enters-into-a-strategic-collaboration-with https://www.adaptimmune.com/investors-and-media/news-center/press-releases/detail/196/adaptimmune-updates-data-from-its-phase-1-trial-for-liver https://www.adaptimmune.com/investors-and-media/news-center/press-releases/detail/195/adaptimmune-reports-second-quarter-financial-results-and https://www.adaptimmune.com/investors-and-media/news-center/press-releases/detail/194/adaptimmune-to-report-q2-2021-financial-results-and https://www.adaptimmune.com/investors-and-media/news-center/press-releases/detail/193/two-complete-responses-and-response-rate-of-41-for-people https://www.adaptimmune.com/investors-and-media/news-center/press-releases/detail/192/first-preclinical-data-from-adaptimmunes-mesothelin-hit https://www.adaptimmune.com/investors-and-media/news-center/press-releases/detail/191/adaptimmune-reports-first-quarter-financial-results-and https://www.adaptimmune.com/investors-and-media/news-center/press-releases/detail/190/adaptimmune-to-present-first-preclinical-data-from-its https://www.adaptimmune.com/investors-and-media/news-center/press-releases/detail/189/adaptimmune-to-report-q1-2021-financial-results-and https://www.adaptimmune.com/investors-and-media/news-center/press-releases/detail/188/adaptimmune-reports-fourth-quarter-full-year-2020 https://www.adaptimmune.com/investors-and-media/news-center/press-releases/detail/187/adaptimmune-to-report-fourth-quarter-full-year-2020 https://www.adaptimmune.com/investors-and-media/news-center/press-releases/detail/186/adaptimmune-to-showcase-market-potential-for-spear-t-cell https://www.adaptimmune.com/investors-and-media/news-center/press-releases/detail/185/durable-responses-with-adp-a2m4-in-synovial-sarcoma-with https://www.adaptimmune.com/investors-and-media/news-center/press-releases/detail/184/adaptimmune-to-host-virtual-investor-day-on-friday https://www.adaptimmune.com/investors-and-media/news-center/press-releases/detail/183/two-confirmed-responses-and-five-out-of-six-patients-with https://www.adaptimmune.com/investors-and-media/news-center/press-releases/detail/182/adaptimmune-reports-q3-financial-results-and-business-update https://www.adaptimmune.com/investors-and-media/news-center/press-releases/detail/181/adaptimmune-to-report-q3-financial-results-and-business https://www.adaptimmune.com/investors-and-media/news-center/press-releases/detail/180/adaptimmune-provides-full-contents-of-its-sitc-abstract-for https://www.adaptimmune.com/investors-and-media/news-center/press-releases/detail/179/promising-data-from-phase-1-trial-with-adp-a2afp-in-liver https://www.adaptimmune.com/investors-and-media/news-center/press-releases/detail/178/adaptimmune-reports-q2-financial-results-and-business-update https://www.adaptimmune.com/investors-and-media/news-center/press-releases/detail/177/adaptimmune-granted-access-to-priority-medicines-prime https://www.adaptimmune.com/investors-and-media/news-center/press-releases/detail/176/adaptimmune-to-report-q2-financial-results-and-business https://www.adaptimmune.com/investors-and-media/news-center/press-releases/detail/175/adaptimmune-therapeutics-plc-announces-closing-of-public https://www.adaptimmune.com/investors-and-media/news-center/press-releases/detail/174/adaptimmune-therapeutics-plc-prices-public-offering-of https://www.adaptimmune.com/investors-and-media/news-center/press-releases/detail/173/adaptimmune-therapeutics-plc-proposes-public-offering-of https://www.adaptimmune.com/investors-and-media/news-center/press-releases/detail/172/spear-t-cells-targeting-mage-a4-demonstrate-new-responses https://www.adaptimmune.com/investors-and-media/news-center/press-releases/detail/171/adaptimmune-reports-q1-financial-results https://www.adaptimmune.com/investors-and-media/news-center/press-releases/detail/170/spear-t-cells-derived-from-stem-cells-kill-cancer-targets- https://www.adaptimmune.com/investors-and-media/news-center/press-releases/detail/169/adaptimmune-to-report-q1-financial-results-on-thursday-may https://www.adaptimmune.com/investors-and-media/news-center/press-releases/detail/168/positive-opinion-for-orphan-drug-designation-for-adp-a2m4 https://www.adaptimmune.com/investors-and-media/news-center/press-releases/detail/1/adaptimmune-reports-fourth-quarter-full-year-2019 https://www.adaptimmune.com/investors-and-media/news-center/press-releases/detail/2/adaptimmune-to-report-full-year-q4-2019-financial-results https://www.adaptimmune.com/investors-and-media/news-center/press-releases/detail/3/adaptimmune-announces-appointment-of-gavin-wood-as-chief https://www.adaptimmune.com/investors-and-media/news-center/press-releases/detail/4/adaptimmune-therapeutics-plc-announces-full-exercise-and https://www.adaptimmune.com/investors-and-media/news-center/press-releases/detail/5/adaptimmune-therapeutics-plc-announces-closing-of-public https://www.adaptimmune.com/investors-and-media/news-center/press-releases/detail/6/adaptimmune-therapeutics-plc-prices-public-offering-of https://www.adaptimmune.com/investors-and-media/news-center/press-releases/detail/7/adaptimmune-therapeutics-plc-proposes-public-offering-of https://www.adaptimmune.com/investors-and-media/news-center/press-releases/detail/8/astellas-and-adaptimmune-enter-into-agreement-to-co-develop https://www.adaptimmune.com/investors-and-media/news-center/press-releases/detail/9/adaptimmune-appoints-elliot-norry-as-chief-medical-officer https://www.adaptimmune.com/investors-and-media/news-center/press-releases/detail/10/adaptimmune-announces-that-spear-t-cell-platform-delivers https://www.adaptimmune.com/investors-and-media/news-center/press-releases/detail/11/regenerative-medicine-advanced-therapy-designation-granted https://www.adaptimmune.com/investors-and-media/news-center/press-releases/detail/12/updated-data-from-phase-1-adp-a2m4-trial-demonstrating https://www.adaptimmune.com/investors-and-media/news-center/press-releases/detail/13/adaptimmune-reports-third-quarter-2019-financial-results https://www.adaptimmune.com/investors-and-media/news-center/press-releases/detail/14/adaptimmune-to-report-third-quarter-2019-financial-results https://www.adaptimmune.com/investors-and-media/news-center/press-releases/detail/15/adaptimmune-and-cryoport-announce-agreement-to-ensure-safe https://www.adaptimmune.com/investors-and-media/news-center/press-releases/detail/16/adaptimmune-announces-appointment-of-michael-garone-as https://www.adaptimmune.com/investors-and-media/news-center/press-releases/detail/17/clear-benefit-for-patients-with-synovial-sarcoma https://www.adaptimmune.com/investors-and-media/news-center/press-releases/detail/18/united-states-orphan-drug-designation-for-treatment-of-soft https://www.adaptimmune.com/investors-and-media/news-center/press-releases/detail/19/adaptimmune-and-noile-immune-announce-agreement-to-develop https://www.adaptimmune.com/investors-and-media/news-center/press-releases/detail/21/new-executive-team-announced-at-adaptimmune https://www.adaptimmune.com/investors-and-media/news-center/press-releases/detail/20/adaptimmune-reports-second-quarter-2019-financial-results https://www.adaptimmune.com/investors-and-media/news-center/press-releases/detail/22/adaptimmune-to-report-second-quarter-2019-financial-results https://www.adaptimmune.com/investors-and-media/news-center/press-releases/detail/23/adaptimmune-starts-spearhead-1-trial-with-adp-a2m4-spear https://www.adaptimmune.com/investors-and-media/news-center/press-releases/detail/24/adaptimmune-has-initiated-a-radiation-sub-study-to-enhance https://www.adaptimmune.com/investors-and-media/news-center/press-releases/detail/25/adaptimmune-starts-the-surpass-clinical-trial-with-its https://www.adaptimmune.com/investors-and-media/news-center/press-releases/detail/26/adrian-rawcliffe-to-succeed-james-noble-as-adaptimmune https://www.adaptimmune.com/investors-and-media/news-center/press-releases/detail/27/adaptimmune-and-alpine-immune-sciences-announce https://www.adaptimmune.com/investors-and-media/news-center/press-releases/detail/28/adaptimmune-reports-first-quarter-2019-financial-results https://www.adaptimmune.com/investors-and-media/news-center/press-releases/detail/29/significant-clinical-progress-as-adaptimmune-announces https://www.adaptimmune.com/investors-and-media/news-center/press-releases/detail/30/adaptimmune-to-present-data-demonstrating-that-its https://www.adaptimmune.com/investors-and-media/news-center/press-releases/detail/31/adaptimmune-to-provide-clinical-and-business-update-on https://www.adaptimmune.com/investors-and-media/news-center/press-releases/detail/32/adaptimmune-announces-oral-presentation-of-allogeneic-spear https://www.adaptimmune.com/investors-and-media/news-center/press-releases/detail/33/adaptimmune-presents-safety-data-with-evidence-of-tumor https://www.adaptimmune.com/investors-and-media/news-center/press-releases/detail/34/adaptimmune-presents-preclinical-data-for-its-next https://www.adaptimmune.com/investors-and-media/news-center/press-releases/detail/35/correcting-and-replacing----adaptimmune-reports-fourth https://www.adaptimmune.com/investors-and-media/news-center/press-releases/detail/36/adaptimmune-reports-fourth-quarter-full-year-2018 https://www.adaptimmune.com/investors-and-media/news-center/press-releases/detail/37/adaptimmune-to-report-fourth-quarter-full-year-2018 https://www.adaptimmune.com/investors-and-media/news-center/press-releases/detail/38/dose-escalation-in-liver-cancer-study-with-adp-a2afp-afp https://www.adaptimmune.com/investors-and-media/news-center/press-releases/detail/39/adaptimmune-announces-that-gwen-binder-will-leave-in https://www.adaptimmune.com/investors-and-media/news-center/press-releases/detail/40/adaptimmune-reports-third-quarter-2018-financial-results https://www.adaptimmune.com/investors-and-media/news-center/press-releases/detail/41/adaptimmune-to-report-third-quarter-2018-financial-results https://www.adaptimmune.com/investors-and-media/news-center/press-releases/detail/42/updated-data-from-ongoing-mage-a10-and-mage-a4-studies https://www.adaptimmune.com/investors-and-media/news-center/press-releases/detail/43/data-updates-from-ongoing-mage-a10-studies-and-mage-a4 https://www.adaptimmune.com/investors-and-media/news-center/press-releases/detail/44/adaptimmune-therapeutics-plc-announces-closing-of https://www.adaptimmune.com/investors-and-media/news-center/press-releases/detail/45/adaptimmune-therapeutics-plc-announces-registered-direct https://www.adaptimmune.com/investors-and-media/news-center/press-releases/detail/46/third-dosing-cohort-to-be-initiated-in-mage-a4-spear-t-cell https://www.adaptimmune.com/investors-and-media/news-center/press-releases/detail/47/adaptimmune-reports-second-quarter-2018-financial-results https://www.adaptimmune.com/investors-and-media/news-center/press-releases/detail/48/adaptimmune-to-report-second-quarter-2018-financial-results https://www.adaptimmune.com/investors-and-media/news-center/press-releases/detail/49/gsk-and-adaptimmune-complete-transition-of-ny-eso-spear https://www.adaptimmune.com/investors-and-media/news-center/press-releases/detail/50/adaptimmune-announces-favorable-review-of-safety-from-one https://www.adaptimmune.com/investors-and-media/news-center/press-releases/detail/51/study-published-in-cancer-discovery-indicates-that-ny-eso https://www.adaptimmune.com/investors-and-media/news-center/press-releases/detail/53/adaptimmune-presents-detailed-safety-update-from-ongoing https://www.adaptimmune.com/investors-and-media/news-center/press-releases/detail/52/adaptimmune-announces-first-patient-to-receive-one-billion https://www.adaptimmune.com/investors-and-media/news-center/press-releases/detail/54/updated-myxoidround-cell-liposarcoma-data-with-ny-eso https://www.adaptimmune.com/investors-and-media/news-center/press-releases/detail/55/myxoidround-cell-liposarcoma-data-with-ny-eso-and-mage-a10 https://www.adaptimmune.com/investors-and-media/news-center/press-releases/detail/56/adaptimmune-reports-first-quarter-2018-financial-results https://www.adaptimmune.com/investors-and-media/news-center/press-releases/detail/57/adaptimmune-to-report-first-quarter-2018-financial-results https://www.adaptimmune.com/investors-and-media/news-center/press-releases/detail/58/adaptimmune-presents-mage-a4-and-mage-a10-pre-clinical-data https://www.adaptimmune.com/investors-and-media/news-center/press-releases/detail/59/adaptimmune-announces-changes-to-board-of-directors https://www.adaptimmune.com/investors-and-media/news-center/press-releases/detail/60/adaptimmune-to-present-two-posters-at-the-upcoming-american https://www.adaptimmune.com/investors-and-media/news-center/press-releases/detail/62/adaptimmune-announces-responses-in-second-solid-tumor https://www.adaptimmune.com/investors-and-media/news-center/press-releases/detail/61/adaptimmune-reports-fourth-quarter-full-year-2017 https://www.adaptimmune.com/investors-and-media/news-center/press-releases/detail/63/adaptimmune-to-report-fourth-quarter-full-year-2017 https://www.adaptimmune.com/investors-and-media/news-center/press-releases/detail/65/adaptimmune-announces-two-manufacturing-achievements-on-its https://www.adaptimmune.com/investors-and-media/news-center/press-releases/detail/64/adaptimmune-announces-positive-safety-data-from-pilot https://www.adaptimmune.com/investors-and-media/news-center/press-releases/detail/66/paul-stead-joins-adaptimmune-as-vice-president-of-business https://www.adaptimmune.com/investors-and-media/news-center/press-releases/detail/67/adaptimmune-data-presented-at-american-society-of https://www.adaptimmune.com/investors-and-media/news-center/press-releases/detail/68/adaptimmune-data-to-be-presented-at-american-society-of https://www.adaptimmune.com/investors-and-media/news-center/press-releases/detail/69/adaptimmune-presents-study-designs-for-ongoing-mage-a4-and https://www.adaptimmune.com/investors-and-media/news-center/press-releases/detail/70/ny-eso-data-presented-at-the-connective-tissue-oncology https://www.adaptimmune.com/investors-and-media/news-center/press-releases/detail/71/adaptimmune-marks-official-opening-of-u-k-headquarters https://www.adaptimmune.com/investors-and-media/news-center/press-releases/detail/72/adaptimmune-to-present-two-trials-in-progress-posters-at https://www.adaptimmune.com/investors-and-media/news-center/press-releases/detail/73/adaptimmune-data-to-be-presented-in-an-oral-presentation https://www.adaptimmune.com/investors-and-media/news-center/press-releases/detail/74/adaptimmune-reports-third-quarter-2017-financial-results https://www.adaptimmune.com/investors-and-media/news-center/press-releases/detail/75/adaptimmune-to-report-third-quarter-2017-financial-results https://www.adaptimmune.com/investors-and-media/news-center/press-releases/detail/76/sbastien-desprez-joins-adaptimmune-as-vice-president-of https://www.adaptimmune.com/investors-and-media/news-center/press-releases/detail/77/james-noble-adaptimmune-ceo-to-participate-in-upcoming https://www.adaptimmune.com/investors-and-media/news-center/press-releases/detail/78/gsk-exercises-option-over-spear-t-cell-therapy-program https://www.adaptimmune.com/investors-and-media/news-center/press-releases/detail/79/adaptimmune-to-present-at-upcoming-car-tcr-summit-ceo https://www.adaptimmune.com/investors-and-media/news-center/press-releases/detail/80/adaptimmune-reports-second-quarter-2017-financial-results https://www.adaptimmune.com/investors-and-media/news-center/press-releases/detail/81/adaptimmune-to-report-second-quarter-2017-financial-results https://www.adaptimmune.com/investors-and-media/news-center/press-releases/detail/82/adaptimmune-announces-an-oral-presentation-on-data-from https://www.adaptimmune.com/investors-and-media/news-center/press-releases/detail/83/adaptimmune-announces-an-oral-presentation-and-four-trials https://www.adaptimmune.com/investors-and-media/news-center/press-releases/detail/84/adaptimmune-announces-initiation-of-study-to-evaluate-spear https://www.adaptimmune.com/investors-and-media/news-center/press-releases/detail/85/adaptimmune-announces-initiation-of-study-to-evaluate-spear https://www.adaptimmune.com/investors-and-media/news-center/press-releases/detail/87/adaptimmune-announces-initiation-of-study-to-evaluate-spear https://www.adaptimmune.com/investors-and-media/news-center/press-releases/detail/86/adaptimmune-reports-first-quarter-2017-financial-results https://www.adaptimmune.com/investors-and-media/news-center/press-releases/detail/88/adaptimmune-to-report-first-quarter-2017-financial-results https://www.adaptimmune.com/investors-and-media/news-center/press-releases/detail/89/adaptimmune-to-present-at-upcoming-deutsche-bank-42nd https://www.adaptimmune.com/investors-and-media/news-center/press-releases/detail/90/adaptimmune-therapeutics-plc-announces-closing-of-42 https://www.adaptimmune.com/investors-and-media/news-center/press-releases/detail/91/adaptimmune-therapeutics-plc-announces-registered-direct https://www.adaptimmune.com/investors-and-media/news-center/press-releases/detail/92/adaptimmune-to-participate-in-upcoming-jefferies https://www.adaptimmune.com/investors-and-media/news-center/press-releases/detail/93/adaptimmune-therapeutics-plc-announces-closing-of-public https://www.adaptimmune.com/investors-and-media/news-center/press-releases/detail/94/adaptimmune-therapeutics-plc-prices-public-offering-of https://www.adaptimmune.com/investors-and-media/news-center/press-releases/detail/95/adaptimmune-therapeutics-plc-proposes-public-offering-of https://www.adaptimmune.com/investors-and-media/news-center/press-releases/detail/96/adaptimmune-broadens-executive-team https://www.adaptimmune.com/investors-and-media/news-center/press-releases/detail/97/adaptimmune-reports-fourth-quarter-and-full-year-2016 https://www.adaptimmune.com/investors-and-media/news-center/press-releases/detail/98/adaptimmune-to-report-fourth-quarter-and-full-year-2016 https://www.adaptimmune.com/investors-and-media/news-center/press-releases/detail/99/adaptimmune-to-present-at-the-cowen-and-company-37th-annual https://www.adaptimmune.com/investors-and-media/news-center/press-releases/detail/100/adaptimmune-cuts-ribbon-on-u-s-headquarters-at-the-navy https://www.adaptimmune.com/investors-and-media/news-center/press-releases/detail/101/adaptimmune-to-participate-in-upcoming-investor-conference https://www.adaptimmune.com/investors-and-media/news-center/press-releases/detail/103/adaptimmune-confirms-gsk-nomination-of-second-adaptimmune https://www.adaptimmune.com/investors-and-media/news-center/press-releases/detail/102/adaptimmune-announces-new-senior-vice-president-of-global https://www.adaptimmune.com/investors-and-media/news-center/press-releases/detail/104/adaptimmune-announces-fda-acceptance-of-ind-application-for https://www.adaptimmune.com/investors-and-media/news-center/press-releases/detail/105/adaptimmune-and-bellicum-pharmaceuticals-enter-a-strategic https://www.adaptimmune.com/investors-and-media/news-center/press-releases/detail/106/adaptimmune-announces-initiation-of-myxoidround-cell https://www.adaptimmune.com/investors-and-media/news-center/press-releases/detail/107/adaptimmune-announces-update-on-clinical-data-from-ny-eso https://www.adaptimmune.com/investors-and-media/news-center/press-releases/detail/108/adaptimmune-presents-preclinical-data-from-a-new https://www.adaptimmune.com/investors-and-media/news-center/press-releases/detail/109/adaptimmune-reports-third-quarter-2016-financial-results https://www.adaptimmune.com/investors-and-media/news-center/press-releases/detail/110/adaptimmune-announces-removal-of-partial-clinical-hold-in https://www.adaptimmune.com/investors-and-media/news-center/press-releases/detail/111/adaptimmune-announces-appointment-of-tal-zaks-to-board-of https://www.adaptimmune.com/investors-and-media/news-center/press-releases/detail/112/adaptimmune-to-present-three-posters-at-the-31st-annual https://www.adaptimmune.com/investors-and-media/news-center/press-releases/detail/113/adaptimmune-to-report-third-quarter-2016-financial-results https://www.adaptimmune.com/investors-and-media/news-center/press-releases/detail/114/adaptimmune-announces-board-changes https://www.adaptimmune.com/investors-and-media/news-center/press-releases/detail/115/adaptimmune-announces-collaboration-with-msd-to-evaluate https://www.adaptimmune.com/investors-and-media/news-center/press-releases/detail/116/adaptimmune-announces-initiation-of-triple-tumor-study-to https://www.adaptimmune.com/investors-and-media/news-center/press-releases/detail/117/adaptimmune-provides-update-on-clinical-study-evaluating https://www.adaptimmune.com/investors-and-media/news-center/press-releases/detail/118/adaptimmune-provides-update-on-study-of-ny-eso-spear https://www.adaptimmune.com/investors-and-media/news-center/press-releases/detail/119/adaptimmune-to-provide-update-on-study-of-ny-eso-spear https://www.adaptimmune.com/investors-and-media/news-center/press-releases/detail/120/md-anderson-cancer-center-and-adaptimmune-form-strategic https://www.adaptimmune.com/investors-and-media/news-center/press-releases/detail/121/adaptimmune-announces-strategic-manufacturing-agreement https://www.adaptimmune.com/investors-and-media/news-center/press-releases/detail/122/adaptimmune-to-participate-in-two-upcoming-investor https://www.adaptimmune.com/investors-and-media/news-center/press-releases/detail/123/adaptimmune-reports-second-quarter-2016-financial-results https://www.adaptimmune.com/investors-and-media/news-center/press-releases/detail/124/adaptimmune-announces-partial-clinical-hold-of-planned https://www.adaptimmune.com/investors-and-media/news-center/press-releases/detail/125/adaptimmune-to-report-second-quarter-2016-financial-results https://www.adaptimmune.com/investors-and-media/news-center/press-releases/detail/126/adaptimmune-receives-access-to-priority-medicines-prime https://www.adaptimmune.com/investors-and-media/news-center/press-releases/detail/127/adaptimmune-receives-orphan-drug-designation-in-the https://www.adaptimmune.com/investors-and-media/news-center/press-releases/detail/128/adaptimmune-announces-commercial-development-and-supply https://www.adaptimmune.com/investors-and-media/news-center/press-releases/detail/129/adaptimmune-receives-positive-opinion-for-orphan-drug https://www.adaptimmune.com/investors-and-media/news-center/press-releases/detail/130/adaptimmune-to-present-at-the-2016-jmp-life-sciences https://www.adaptimmune.com/investors-and-media/news-center/press-releases/detail/131/adaptimmune-announces-data-from-clinical-studies-of https://www.adaptimmune.com/investors-and-media/news-center/press-releases/detail/132/adaptimmune-to-present-at-the-jefferies-2016-healthcare https://www.adaptimmune.com/investors-and-media/news-center/press-releases/detail/133/adaptimmune-announces-succession-plan-for-chairman-at-end https://www.adaptimmune.com/investors-and-media/news-center/press-releases/detail/134/adaptimmune-strengthens-board-with-appointment-of-barbara https://www.adaptimmune.com/investors-and-media/news-center/press-releases/detail/135/adaptimmune-to-present-at-the-2016-ubs-global-healthcare https://www.adaptimmune.com/investors-and-media/news-center/press-releases/detail/136/adaptimmune-reports-first-quarter-2016-financial-results https://www.adaptimmune.com/investors-and-media/news-center/press-releases/detail/137/adaptimmune-to-present-at-the-bank-of-america-merrill-lynch https://www.adaptimmune.com/investors-and-media/news-center/press-releases/detail/138/adaptimmune-to-present-at-the-deutsche-bank-securities-41st https://www.adaptimmune.com/investors-and-media/news-center/press-releases/detail/139/adaptimmune-presents-corporate-and-clinical-updates-at https://www.adaptimmune.com/investors-and-media/news-center/press-releases/detail/140/adaptimmune-announces-spear-t-cells-brand-for https://www.adaptimmune.com/investors-and-media/news-center/press-releases/detail/141/adaptimmune-appoints-leading-immunotherapy-experts-from https://www.adaptimmune.com/investors-and-media/news-center/press-releases/detail/142/adaptimmune-to-host-analyst-and-investor-day-on-april-22 https://www.adaptimmune.com/investors-and-media/news-center/press-releases/detail/143/adaptimmune-announces-new-vice-president-of-business https://www.adaptimmune.com/investors-and-media/news-center/press-releases/detail/144/adaptimmune-announces-fda-acceptance-of-ind-application-for https://www.adaptimmune.com/investors-and-media/news-center/press-releases/detail/145/u-s-food-and-drug-administration-grants-orphan-drug https://www.adaptimmune.com/investors-and-media/news-center/press-releases/detail/146/adaptimmune-reports-financial-results-for-the-six-month https://www.adaptimmune.com/investors-and-media/news-center/press-releases/detail/147/adaptimmune-to-present-at-cowen-and-companys-36th-annual https://www.adaptimmune.com/investors-and-media/news-center/press-releases/detail/148/adaptimmune-to-present-at-the-rbc-capital-markets-global https://www.adaptimmune.com/investors-and-media/news-center/press-releases/detail/149/u-s-food-and-drug-administration-grants-breakthrough https://www.adaptimmune.com/investors-and-media/news-center/press-releases/detail/150/adaptimmune-to-participate-in-two-upcoming-investor https://www.adaptimmune.com/investors-and-media/news-center/press-releases/detail/151/adaptimmune-to-host-conference-call-at-10-00-am-et-3-00-pm https://www.adaptimmune.com/investors-and-media/news-center/press-releases/detail/152/adaptimmune-and-gsk-expand-strategic-immunotherapy https://www.adaptimmune.com/investors-and-media/news-center/press-releases/detail/153/adaptimmune-announces-new-additions-to-manufacturing-senior https://www.adaptimmune.com/investors-and-media/news-center/press-releases/detail/154/adaptimmune-expands-t-cell-engineering-expertise-to-develop https://www.adaptimmune.com/investors-and-media/news-center/press-releases/detail/155/adaptimmune-announces-initiation-of-study-to-evaluate-its https://www.adaptimmune.com/investors-and-media/news-center/press-releases/detail/156/adaptimmune-wins-scrip-award-for-financing-deal-of-the-year https://www.adaptimmune.com/investors-and-media/news-center/press-releases/detail/157/adaptimmune-and-universal-cells-announce-collaboration-to https://www.adaptimmune.com/investors-and-media/news-center/press-releases/detail/158/adaptimmune-initiates-phase-i-ii-trial-evaluating-its https://www.adaptimmune.com/investors-and-media/news-center/press-releases/detail/159/adaptimmune-reports-first-quarter-financial-results-for https://www.adaptimmune.com/investors-and-media/news-center/press-releases/detail/160/adaptimmune-to-participate-in-the-jefferies-autumn-2015 https://www.adaptimmune.com/investors-and-media/news-center/press-releases/detail/161/adaptimmune-announces-data-from-clinical-study-of-ny-eso https://www.adaptimmune.com/investors-and-media/news-center/press-releases/detail/162/adaptimmune-announces-upcoming-data-presentation-at-the https://www.adaptimmune.com/investors-and-media/news-center/press-releases/detail/163/adaptimmune-to-participate-in-the-2015-bio-investor-forum https://www.adaptimmune.com/investors-and-media/news-center/press-releases/detail/164/adaptimmune-reports-full-fiscal-year-2015-financial-results https://www.adaptimmune.com/investors-and-media/news-center/press-releases/detail/165/adaptimmune-growth-leads-to-long-term-expansion-plans-in https://www.adaptimmune.com/investors-and-media/news-center/press-releases/detail/166/adaptimmune-to-report-full-fiscal-year-2015-financial https://www.adaptimmune.com/investors-and-media/news-center/press-releases/detail/167/adaptimmune-announces-new-research-and-development-facility https://www.adaptimmune.com/investors-and-media/news-center/press-releases/detail/206/adaptimmune-to-participate-in-the-leerink-partners https://www.adaptimmune.com/investors-and-media/news-center/press-releases/detail/207/adaptimmune-to-participate-in-two-upcoming-investor https://www.adaptimmune.com/investors-and-media/news-center/press-releases/detail/208/adaptimmune-announces-expansion-of-senior-team-to-augment https://www.adaptimmune.com/investors-and-media/news-center/press-releases/detail/209/adaptimmune-to-participate-in-the-22nd-annual-biocentury https://www.adaptimmune.com/investors-and-media/news-center/press-releases/detail/210/adaptimmune-expands-trial-of-t-cell-therapy-for-synovial https://www.adaptimmune.com/investors-and-media/news-center/press-releases/detail/211/adaptimmune-to-participate-in-the-wedbush-2015-life https://www.adaptimmune.com/investors-and-media/news-center/press-releases/detail/212/adaptimmunes-ny-eso-1-tcr-engineered-t-cells-demonstrate https://www.adaptimmune.com/investors-and-media/news-center/press-releases/detail/213/adaptimmune-announces-fda-acceptance-of-investigational-new https://www.adaptimmune.com/investors-and-media/news-center/press-releases/detail/214/adaptimmune-announces-data-from-clinical-studies-of https://www.adaptimmune.com/investors-and-media/news-center/press-releases/detail/215/adaptimmune-announces-upcoming-data-presentation-at-the https://www.adaptimmune.com/investors-and-media/news-center/press-releases/detail/216/adaptimmune-announces-new-additions-to-senior-clinical https://www.adaptimmune.com/investors-and-media/news-center/press-releases/detail/217/adaptimmune-announces-upcoming-data-presentation-at-the https://www.adaptimmune.com/investors-and-media/news-center/press-releases/detail/218/adaptimmune-announces-appointment-of-vice-president-of https://www.adaptimmune.com/investors-and-media/news-center/press-releases/detail/219/adaptimmune-announces-closing-of-initial-public-offering https://www.adaptimmune.com/investors-and-media/news-center/press-releases/detail/220/adaptimmune-announces-pricing-of-initial-public-offering https://www.adaptimmune.com/privacy-policy https://www.adaptimmune.com/search https://www.adaptimmune.com/sitemap https://www.adaptimmune.com/terms-of-use